Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia

Mrinal M. Patnaik; David A. Sallman; Abhishek A. Mangaonkar; Rachel Heuer; Jeffery Hirvela; Darci Zblewski; Aref Al-Kali; Moritz Binder; Maria E. Balasis; Hannah Newman; Christopher Letson; Traci L. Kruer; Naseema Gangat; Rami S. Komrokji; Ayalew Tefferi; Adrian Lo; Ted Shih; Cameron Durrant; Alan F. List; Eric Padron

doi:10.1182/blood.2019004352

Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia

Mrinal M. Patnaik, David A. Sallman, Abhishek A. Mangaonkar, Rachel Heuer, Jeffery Hirvela, Darci Zblewski, Aref Al-Kali, Moritz Binder, Maria E. Balasis, Hannah Newman, Christopher Letson, Traci L. Kruer, Naseema Gangat, Rami S. Komrokji, Ayalew Tefferi, Adrian Lo, Ted Shih, Cameron Durrant, Alan F. List, Eric Padron

Hematology

Research output: Contribution to journal › Letter › peer-review

17 Scopus citations

Original language	English (US)
Pages (from-to)	909-913
Number of pages	5
Journal	Blood
Volume	136
Issue number	7
DOIs	https://doi.org/10.1182/blood.2019004352
State	Published - Aug 13 2020

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2019004352

Cite this

Patnaik, M. M., Sallman, D. A., Mangaonkar, A. A., Heuer, R., Hirvela, J., Zblewski, D., Al-Kali, A., Binder, M., Balasis, M. E., Newman, H., Letson, C., Kruer, T. L., Gangat, N., Komrokji, R. S., Tefferi, A., Lo, A., Shih, T., Durrant, C., List, A. F., & Padron, E. (2020). Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood, 136(7), 909-913. https://doi.org/10.1182/blood.2019004352

Patnaik, MM, Sallman, DA, Mangaonkar, AA, Heuer, R, Hirvela, J, Zblewski, D, Al-Kali, A, Binder, M, Balasis, ME, Newman, H, Letson, C, Kruer, TL, Gangat, N, Komrokji, RS, Tefferi, A, Lo, A, Shih, T, Durrant, C, List, AF & Padron, E 2020, 'Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia', Blood, vol. 136, no. 7, pp. 909-913. https://doi.org/10.1182/blood.2019004352

@article{a32f51f225db4360be8bf5d7ca8d78fa,

title = "Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia",

author = "Patnaik, {Mrinal M.} and Sallman, {David A.} and Mangaonkar, {Abhishek A.} and Rachel Heuer and Jeffery Hirvela and Darci Zblewski and Aref Al-Kali and Moritz Binder and Balasis, {Maria E.} and Hannah Newman and Christopher Letson and Kruer, {Traci L.} and Naseema Gangat and Komrokji, {Rami S.} and Ayalew Tefferi and Adrian Lo and Ted Shih and Cameron Durrant and List, {Alan F.} and Eric Padron",

note = "Funding Information: Conflict-of-interest disclosure: M.M.P. has served on the advisory board for Stemline Therapeutics. A.F.L. has received research funding from and has served as a consultant for Celgene and serves as a scientific advisor for Cellular Biomedicine Group and Aileron Therapeutics, Inc. E.P. has received research funding from Humanigen Inc. (formerly",

year = "2020",

month = aug,

day = "13",

doi = "10.1182/blood.2019004352",

language = "English (US)",

volume = "136",

pages = "909--913",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "7",

}

TY - JOUR

T1 - Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia

AU - Patnaik, Mrinal M.

AU - Sallman, David A.

AU - Mangaonkar, Abhishek A.

AU - Heuer, Rachel

AU - Hirvela, Jeffery

AU - Zblewski, Darci

AU - Al-Kali, Aref

AU - Binder, Moritz

AU - Balasis, Maria E.

AU - Newman, Hannah

AU - Letson, Christopher

AU - Kruer, Traci L.

AU - Gangat, Naseema

AU - Komrokji, Rami S.

AU - Tefferi, Ayalew

AU - Lo, Adrian

AU - Shih, Ted

AU - Durrant, Cameron

AU - List, Alan F.

AU - Padron, Eric

N1 - Funding Information: Conflict-of-interest disclosure: M.M.P. has served on the advisory board for Stemline Therapeutics. A.F.L. has received research funding from and has served as a consultant for Celgene and serves as a scientific advisor for Cellular Biomedicine Group and Aileron Therapeutics, Inc. E.P. has received research funding from Humanigen Inc. (formerly

PY - 2020/8/13

Y1 - 2020/8/13

UR - http://www.scopus.com/inward/record.url?scp=85088198315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088198315&partnerID=8YFLogxK

U2 - 10.1182/blood.2019004352

DO - 10.1182/blood.2019004352

M3 - Letter

C2 - 32294158

AN - SCOPUS:85088198315

SN - 0006-4971

VL - 136

SP - 909

EP - 913

JO - Blood

JF - Blood

IS - 7

ER -

Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this